Kornimate/medical-research-clean huggingface dataset:
psma-pet imaging in patients with metastatic prostate cancer: institutional evaluation of detection yield performance and reproducibility

Conditions: Prostate Cancer

Summary: a promising imaging technique involving new prostate specific membrane antigen (psma) positron emission tomography (pet) tracers is emerging in metastatic prostate cancer (pca). this approach has demonstrated higher sensitivity in detecting metastases, prior to and during therapy, than current imaging standard of care (ct and bone scan). psma is expressed in the vast majority of pca tissue specimens and its degree of expression correlates with a number of important metrics of pca tumor aggressiveness. \[18f\]dcfpyl is a promising high-sensitivity second generation psma-targeted urea-based pet probe. studies employing second-generation psma pet/ct imaging in men with biochemical progression after definitive therapy suggest detection of metastases in over 60% of men imaged. in fact, psma-based pet has so far proven to have higher sensitivity than any other modality for localization of the site of recurrence. applications that show promise and require further investigation include the characterization and risk stratification of primary pca, complete staging of metastatic pca to allow for psma-targeted radiotherapy and improved identification of patients with oligometastatic disease. the objective of this study is to explore the detection yield of psma-pet in a pilot cohort of patients at chum and establish the repeatability of the technique before investigating it more widely.


Eligibility criteria:
inclusion criteria: * ability to provide informed consent * metastatic prostate cancer. * at least 18 years of age * standard imaging (bone scan, ct abdo/pelvis/chest) within 6 weeks of consent. exclusion criteria: -
aromatherapy effect on anxiety prior to ultrasound guided musculoskeletal procedures

Conditions: Anxiety State

Summary: the goal of this study is to evaluate the effect of lavender essential oil on pre-procedure anxiety for patients undergoing ultrasound guided musculoskeletal procedures


Eligibility criteria:
inclusion criteria: adults ages 18-85. those undergoing ultrasound guided musculoskeletal procedures including joint, tendon, bursa, or periarticular structure injection/ aspiration. proficient with english. exclusion criteria: patients currently on benzodiazepine anxiolytic therapy those with significantly impaired sense of smell allergy/aversion to lavender essential oils patients with asthma patients with history of migraines patients with any other condition that, in the opinion of the investigator, would compromise the well-being of the patient or prevent the patient from meeting or performing study requirements adults unable to consent individuals who are not yet adults pregnant women prisoners
genome wide snp array-based approach to detect micro-cytogenetic lesions and kit mutation to improve treatment outcomes in patients with core-binding factor positive acute myeloid leukemia

Conditions: Myeloid Leukemia

Summary: core binding factor (cbf) positive acute myeloid leukemia (aml) consist of 15% of patients in overall aml, expected to harbor a favorable prognosis. however, around a half of cases relapses. accordingly, more sophisticated classification in cbf positive amls is essential to achieve further improvement in the treatment outcome. the current study is designed to evaluate cbf positive aml patients with genome-wide snp array and kit mutation study in cbf positive aml patients diagnosed at the samsung medical center and hwasun chonnam national university hospital, korea between 1994 and 2008. 1. construction of the cbf positive aml patient cohort: clinical database establishment (including treatment outcomes and prognosis) and extraction/storage of tumor cell dnas from marrow samples, then processing of affymetrix snp array 6.0. 2. construction of prognostic predictive model using pharmacogenomics with the results of genotypes and copy number variations (cnvs). 3. detection of hidden microscopic cytogenetic lesions with snp array technique, and correlation with clinical outcomes in cbf positive aml. 4. detection of kit, flt3/itd, and npm1 gene mutation and its correlation with clinical outcomes in cbf positive aml. the current study attempts to analyze genetic data of core binding factor (cbf) positive acute myeloid leukemia (aml) using genome wide snp array technique with tumor dnas collected at the time of diagnosis. 1. to detect microcytogenetic lesions and will analyze its prognostic significance 2. to analyze genome-wide genotypes and copy number variations (cnvs) using pharmacogenetic approach and will construct a prognostic predictive model 3. to detect kit, flt3/itd and npm1 mutation and evaluate its prognostic significance. the present study will establish individualized therapy for cbf positive aml, will provide a basis for molecular marker guided clinical trial in cbf positive aml.


Eligibility criteria:
inclusion criteria: * patients with core binding factor positive acute myeloid leukemia * 18 years or older * patients were treated with standard chemotherapy * patients with available medical record and stored bone marrow specimen at time of diagnosis exclusion criteria: * no definive criteria

Keywords: genome wide snp-array micro-cytogenetic lesion kit mutation core binding factor acute myeloid leukemia the approval status was changed from pending to approved.
clinical assessment of patients with chronic obstructive pulmonary disease (copd) and/or chronic heart failure (chf)

Conditions: COPD; Heart Failure, Congestive

Summary: cigarette smoking, the major risk factor for copd, causes not only airway and lung inflammation, but also systemic effects. these systemic effects of smoking could substantially contribute to the development of chronic diseases, other than copd, particularly chronic heart failure (chf). the aim of this project is to assess the frequency and severity of chf and copd in outpatients with history of smoking referred to hospital because of dyspnea and/or chronic cough.

we will recruit 100 patients older than 50 years with diagnosis of copd and/or chf. copd is defined by presence of fixed airflow obstruction (post-bronchodilator fev1/fvc less than 70%) according to global initiative for obstructive lung disease (gold) guidelines. each patient will be characterized by medical history and physical examination. patients with a diagnosis of copd must have: 1) had a history of chronic respiratory symptoms, i.e., cough and sputum and/or breathlessness and only occasional wheezing (sgrq and mmrc questionnaire); 2) they had to be smokers or ex-smokers with more than 10 pack-years, and 3) a documented absence of a history of variable airflow obstruction and/or diagnosis of asthma. each patient will perform pulmonary function tests, including reversibility to inhaled bronchodilator (400 µg albuterol); arterial blood gases, and routine blood tests. in addition, each patient will undergo regular pa/ll chest x-ray. the diagnosis of chf is established according to the criteria of european society of cardiology. at time of entry in the study, all patients will be in clinically stable condition (ie, no changes in medication dosage or frequency, and no exacerbations of disease or hospital admissions in the preceding 6 weeks). clinical and biological follow-up of these patients will be prospectively followed for 2 years, from 2009 to 2011.

Eligibility criteria:
inclusion criteria: * caucasians * males and females * age \> 50 years * smoking history \> 10 pack years * diagnosis of copd according to gold 2008 and/or diagnosis of chf according to esc 2008 exclusion criteria: * history of bronchial asthma * fixed airflow limitation due to other chronic diseases such as cystic fibrosis, bronchiolitis obliterans organizing pneumonia (boop), bronchiectasis, tbc etc. * combined restrictive-obstructive functional impairment

Keywords: smoking dyspnea cough exercise
effectiveness of gum chewing on ileus in chinese colorectal patients underwent laparoscopic colorectal surgery

Conditions: Colorectal Cancer

Summary: gum chewing group will have less ileus and early resume of bowel motion than control group.

the standardize surgical techniques, less used of epidural analgesia, early ambulation and used of naso-gastric tube for decompression are aimed to reduce the paralytic ileus after abdominal surgery . most western studies have examined and found that gum chewing are able to prevent postoperative ileus or promotes early bowel function after abdominal surgery.

Eligibility criteria:
inclusion criteria: * patients with newly diagnosed colorectal cancer undergoing laparoscopic resection in in queen mary hospital * at least 18 years * speak cantonese * able to follow study protocol and chewing gum study exclusion criteria: * cognitive disability * requirement of epidural analgesia * requirement of intensive care unit/ high dependency unit care postoperatively * inability to chew * presence of procedure other than colorectal resection * non chinese
enhanced external counter pulsation on afterload mismatch rate in post-teer (pamper)

Conditions: Mitral Regurgitation

Summary: the goal of this multicenter, randomized, double-blind controlled study is to learn about the individuals after transcatheter edge-to-edge mitral valve repair (teer). the main questions it aims to answer are: (1) can enhanced external counterpulsation (eecp) reduce the prevalence of afterload mismatch after teer? (2) can eecp prevent the major adverse cardiac events after teer? participants will be randomly assigned into eecp or sham-eecp intervention after teer. researchers will compare the eecp and sham-eecp to see if it helps reduce the prevalence of afterload mismatch after teer.


Eligibility criteria:
inclusion criteria * consent to participate * age \> 18 years * moderate or severe mitral regurgitation * patients who meet the indications for transcatheter mitral valve edge-to-edge repair and have undergone teerm exclusion criteria * lower extremity deep vein thrombosis, active thrombophlebitis * moderate or severe aortic stenosis/insufficiency * moderate pulmonary hypertension (mean pulmonary pressure \>50mmhg) * aortic aneurysm/cerebral aneurysm uncontrolled hypertension (\>180/110mmhg) arrhythmias that may interfere with the ecg gating function of the eecp device hemorrhagic disease or obvious bleeding tendency limb infection pregnant/lactating women
oks for gait instability

Conditions: Gait, Unsteady; Vestibular Disorder

Summary: specific aim: to determine whether optokinetic stimulation can improve gait abnormalities. hypothesis: optokinetic stimulation stimulates the vestibular system and can improve vestibular induced gait disorders.

this is a pilot study designed to determine whether or not the optokinetic stimulation improves gait in patients with gait abnormalities, specifically vestibular induced gait disorders. the study population will consist of patients already receiving a gait assessment through the brain fit club (bfc) at beth israel deaconess medical center. this gait assessment involves walking and posture evaluations. patients will complete a gait assessment as part of their normal bfc evaluation. those who consent to participate in the study will then complete a gait assessment while receiving optokinetic stimulation. the investigators will compare baseline gait and postural control before and during oks stimulation.

Eligibility criteria:
inclusion criteria: * receiving a gait assessment through the bfc * ages 21-75 exclusion criteria: * left hemiparesis * requires a cane or walker * documented evidence of falls or instability to the left * reduced vision * moderate or severe dementia
trop-shock dft-testing versus none

Conditions: Defibrillation Testing - ICD Therapy Optimisation

Summary: implantation of a cardioverter defibrillator (icd) is the treatment of choice for primary and secondary prevention of sudden cardiac death. traditionally, intraoperative testing for sensing and defibrillation capabilities of the icd system is performed. modern implantation strategies suggest a non-testing approach because net-benefit of a testing versus a non-testing strategy is questionable and because arrhythmia induction and defibrillation may cause micro damage to the heart. the study aims to investigate the contribution of different steps in the icd implantation procedure (implantation of the lead, shock delivery and induced ventricular fibrillation) with respect to their potential damage to the heart measured by high sensitivity (hs) troponint.


Eligibility criteria:
inclusion criteria: * icd-implantation in patients with coronary artery disease or dilative cardiomyopathy exclusion criteria: * atrial fibrillation with inappropriate anticoagulation

Keywords: icd dft-testing
intra-operative radiotherapy for breast cancer women after nsm

Conditions: Breast Neoplasms

Summary: the role of nsm is still controversial, mainly because of concern about the oncologic safety of the nipple-areola complex (nac).intrabeam (carl zeiss, oberkochen, germany) is the most widely used mobile intraoperative radiotherapy (iort) device to date. this study aims to assess the value of the intrabeam system for breast cancer.

despite the advancement and increasing use of nipple-sparing mastectomy (nsm) is still carried out in a portion of breast cancer patients. however, the role of nsm is still controversial, mainly because of concern about the oncologic safety of the nipple-areola complex (nac). radiation therapy uses high-energy x-rays to damage tumor cells. giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.intrabeam (carl zeiss, oberkochen, germany) is the most widely used mobile intraoperative radiotherapy (iort) device to date. this study aims to broaden the application of the intrabeam system for breast cancer, investigating the feasibility of intrabeam iort in nsm with breast reconstruction.

Eligibility criteria:
inclusion criteria: * tumor diameter ≤3 cm * tumor from the papilla\>2cm * low grade ductal carcinoma in situ * candidate for breast-conserving surgery * must have undergone lumpectomy with negative margins or minimal margin involvement * currently undergoing re-excision of the biopsy cavity and/or sentinel lymph node biopsy or axillary lymph node dissection * no evidence of metastatic disease * informed consent exclusion criteria: * no informed consent * tumor size \> 3 cm * tumor from the papilla≤2cm * intermediate or high grade ductal carcinoma in situ * invasive carcinoma * no indication for a boost

Keywords: ductal carcinoma in situ （dcis） nipple-sparing mastectomy (nsm) intraoperative radiotherapy (iort) intrabeam
a pilot, randomized controlled trial of group visits for persons with parkinson's disease

Conditions: Parkinson's Disease; Parkinson's Disease Patient Caregivers

Summary: to determine patient satisfaction with group visits versus standard of care delivery for patients with parkinson's disease.

to establish the feasibility and to estimate the benefit of group visits for individuals with pd and their caregivers. the feasibility will be assessed by the ability to enroll and retain (measured by number of individuals who complete the 12-month study and at least half the study visits) \~40 individuals in the pilot trial. the responsiveness of the following different outcomes to group visits will be assessed during the pilot trial: quality of life, patient satisfaction, depression, caregiver burden, resource utilization, and disease progression. the primary outcome measure for efficacy will be a comparison of the change in the parkinson's disease questionnaire-39 from baseline to 12 months in the control (routine care) and intervention (group visit) groups.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of idiopathic parkinson's disease as determined by having two of the four cardinal features of pd (rest tremor, bradykinesia, cogwheel rigidity, and gait instability) and no alternative explanation for the etiology of the symptoms * willing and able to provide informed consent and to participate actively in group visits and complete study activities exclusion criteria: * cognitive impairment, psychiatric disorder, or history of or current clinically significant substance abuse that in the investigator's judgment could interfere in the conduct of group visits or with study participation.

Keywords: group visits
pattern and management of intracranial cavernoma

Conditions: Management of Intracranial Cavernous Hemangioma

Summary: intracranial cavernous vascular malformations are variously known as cavernous angiomas, cavernous hemangiomas, or, more simply, cavernomas. cavernomas are congenital low flow vascular lesions. it composed of irregular sinusoidal vascular channels, lacking smooth muscle, and elastic fibers. they lack feeding arteries or draining veins and contain no neural tissue. the first description of an intracranial cavernoma was given by virchow, in 1863. for over a century, it was considered to be an extremely rare malformation, usually found at autopsy, and exceptionally diagnosed during life. the prevalence of cerebral cavernous malformations (ccm) is estimated to be 0.4-0.9%.


Eligibility criteria:
inclusion criteria: * all patients presented with intracranial cavernomas (single or multiple, superficial or deep, supratentorial or infratentorial) * denovo or recurrent patients. exclusion criteria: * none
phase iii study testing efficacy & safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (vte)

Conditions: Thromboembolism

Summary: the general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin pro re nata (as needed/prn) to maintain an international normalised ratio (inr) of 2.0-3.0 for 6 month treatment of acute symptomatic vte. the primary objective is to investigate the efficacy of dabigatran compared to warfarin during the 6 month treatment period. the investigation of other selected efficacy aspects and safety are regarded as secondary objective of this trial.


Eligibility criteria:
inclusion criteria: * acute symptomatic uni- or bilateral deep vein thrombosis (dvt) of the leg involving proximal veins, and/or pulmonary embolism (pe) * male or female, being 18 years of age or older * written informed consent for study participation exclusion criteria: * persistent symptoms of vte * pe requiring urgent intervention * use of vena cava filter * contraindications to anticoagulant therapy * allergy to study medications * elevated aspartate-aminotransferase (ast) or alanine-aminotransferase (alt) \> 3x upper limit of normal (uln) or known liver disease expected to have an impact on survival * severe renal impairment * patients considered unsuitable for inclusion
electrically assisted movement therapy

Conditions: Cerebrovascular Accident

Summary: the purpose of this study is to determine whether intensive, focused training of the affected upper extremity after stroke results in long-term functional gains in moderately-to-severely paralyzed patients, more than 6 months after their vascular accident. during the course of therapy, user's attempts to move and complete exercises are assisted by neuromuscular electrical stimulation.

this pilot study quantifies functional gains induced by the electrically assisted movement therapy (eamt), an extension of constraint-induced movement therapy to moderately-to-severely paralyzed patients in their stable plateau phase of recovery. during eamt, patients can assist affected upper limb movements through functional electrical stimulation. initially, patients are divided in two groups. one of the groups receives eamt, the other receives the best possible physical and occupational therapy. therapy consists in 40 sessions of 45 minutes twice per day over five weeks, including a one-week therapy break. after 20 sessions, group allocation is crossed-over, and patients don't receive any therapy for one week.

Eligibility criteria:
inclusion criteria: * diagnosis of one, first ever stroke (both ischemic or hemorrhagic) verified by brain imaging (mri or ct); * chronic impairment after stroke (minimum 6 months); * no contraindications to mri; * no contraindications to electrical stimulation; exclusion criteria: * unstable recovery stage (difference between two examinations \> 1 fma-ue point); * mild impairment of the upper extremity (fma-ue \>= 21); * excessive spasticity of the affected arm (modified ashworth scale \> 2);
combination chemotherapy plus bevacizumab in treating patients with advanced colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. bevacizumab may stop the growth of colorectal cancer by stopping blood flow to the tumor. purpose: phase ii trial to study the effectiveness of combination chemotherapy plus bevacizumab in treating patients who have advanced colorectal cancer.

objectives: i. determine the progression-free survival at 7 months of patients with previously untreated advanced colorectal cancer treated with fluorouracil, leucovorin calcium, irinotecan, and bevacizumab. ii. determine the response rate and overall survival of this patient population treated with this regimen. iii. determine the toxicity of this treatment regimen in these patients. outline: this is a multicenter study. patients receive irinotecan iv over 90 minutes, leucovorin calcium iv, and fluorouracil iv once weekly for 4 weeks. patients also receive bevacizumab iv over 30-90 minutes once every 2 weeks. treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. projected accrual: a total of 75 patients will be accrued for this study within 1 year.

Eligibility criteria:
disease characteristics: histologically confirmed advanced or metastatic adenocarcinoma of the colon and rectum surgically unresectable disease measurable disease disease outside the prior radiotherapy port and/or progressive disease within the previously irradiated volume patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: not specified hematopoietic: wbc at least 3,000/mm3 platelet count at least 100,000/mm3 no hemorrhagic events within the past 6 months hepatic: bilirubin normal sgot normal inr no greater than 1.5 renal: creatinine no greater than 1.5 times upper limit of normal cardiovascular: no thromboembolic events within the past 6 months pulmonary: no evidence of pneumonia other: no known hypersensitivity to recombinant humanized murine monoclonal antibodies no evidence of significant active infection (e.g., peritonitis or wound abscess) not pregnant or nursing negative pregnancy test fertile patients must use effective contraception prior concurrent therapy: biologic therapy: no concurrent sargramostim (gm-csf) chemotherapy: at least 12 months since prior fluorouracil-based adjuvant chemotherapy no prior adjuvant irinotecan endocrine therapy: not specified radiotherapy: see disease characteristics at least 2 weeks since prior radiotherapy and recovered surgery: see disease characteristics other: no prior therapy for advanced disease no concurrent therapeutic anticoagulation except for low-dose coumadin for maintenance of indwelling catheters

Keywords: stage iv colon cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum